Mackenzie Financial Corp Clovis Oncology, Inc. Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $212,697 - $374,978	-78,777 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$4.06 - $5.8 $10,020 - $14,314	2,468 Added 3.23%	78,777 $351,000
Q2 2021 Aug 11, 2021	BUY	$5.02 - $7.05 $167,211 - $234,828	33,309 Added 77.46%	76,309 $443,000
Q1 2021 May 14, 2021	BUY	$4.81 - $10.34 $206,829 - $444,620	43,000 New	43,000 $302,000
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $475,155 - $761,037	-98,580 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $560,920 - $955,240	98,580 New	98,580 $665,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.